Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
29 10 2021
Historique:
received: 27 04 2021
accepted: 28 10 2021
pubmed: 30 10 2021
medline: 27 1 2022
entrez: 29 10 2021
Statut: epublish

Résumé

Cell-penetrating peptides (CPPs) allow intracellular delivery of bioactive cargo molecules. The mechanisms allowing CPPs to enter cells are ill-defined. Using a CRISPR/Cas9-based screening, we discovered that KCNQ5, KCNN4, and KCNK5 potassium channels positively modulate cationic CPP direct translocation into cells by decreasing the transmembrane potential (V Before a drug can have its desired effect, it must reach its target tissue or organ, and enter its cells. This is not easy because cells are surrounded by the plasma membrane, a fat-based barrier that separates the cell from its external environment. The plasma membrane contains proteins that act as channels, shuttling specific molecules in and out of the cell, and it also holds charge, with its inside surface being more negatively charged than its outside surface. Cell-penetrating peptides are short sequences of amino acids (the building blocks that form proteins) that carry positive charges. These positive charges allow them to cross the membrane easily, but it is not well understood how. To find out how cell-penetrating peptides cross the membrane, Trofimenko et al. attached them to dyes of different sizes. This revealed that the cell-penetrating peptides enter the cell through temporary holes called water pores, which measure about two nanometres across. The water pores form when the membrane becomes ‘megapolarized’, this is, when the difference in charge between the inside and the outside of the membrane becomes greater than normal. This can happen when the negative charge on the inside surface or the positive charge on the outer surface of the membrane increase. Megapolarization depends on potassium channels, which transport positive potassium ions outside the cell, making the outside of the membrane positive. When cell-penetrating peptides arrive at the outer surface of the cell near potassium channels, they make it even more positive. This increases the charge difference between the inside and the outside of the cell, allowing water pores to form. Once the peptides pass through the pores, the charge difference between the inside and the outside of the cell membrane dissipates, and the pores collapse. Drug developers are experimenting with attaching cell-penetrating peptides to drugs to help them get inside their target cells. Currently there are several experimental medications of this kind in clinical trials. Understanding how these peptides gain entry, and what size of molecule they could carry with them, provides solid ground for further drug development.

Autres résumés

Type: plain-language-summary (eng)
Before a drug can have its desired effect, it must reach its target tissue or organ, and enter its cells. This is not easy because cells are surrounded by the plasma membrane, a fat-based barrier that separates the cell from its external environment. The plasma membrane contains proteins that act as channels, shuttling specific molecules in and out of the cell, and it also holds charge, with its inside surface being more negatively charged than its outside surface. Cell-penetrating peptides are short sequences of amino acids (the building blocks that form proteins) that carry positive charges. These positive charges allow them to cross the membrane easily, but it is not well understood how. To find out how cell-penetrating peptides cross the membrane, Trofimenko et al. attached them to dyes of different sizes. This revealed that the cell-penetrating peptides enter the cell through temporary holes called water pores, which measure about two nanometres across. The water pores form when the membrane becomes ‘megapolarized’, this is, when the difference in charge between the inside and the outside of the membrane becomes greater than normal. This can happen when the negative charge on the inside surface or the positive charge on the outer surface of the membrane increase. Megapolarization depends on potassium channels, which transport positive potassium ions outside the cell, making the outside of the membrane positive. When cell-penetrating peptides arrive at the outer surface of the cell near potassium channels, they make it even more positive. This increases the charge difference between the inside and the outside of the cell, allowing water pores to form. Once the peptides pass through the pores, the charge difference between the inside and the outside of the cell membrane dissipates, and the pores collapse. Drug developers are experimenting with attaching cell-penetrating peptides to drugs to help them get inside their target cells. Currently there are several experimental medications of this kind in clinical trials. Understanding how these peptides gain entry, and what size of molecule they could carry with them, provides solid ground for further drug development.

Identifiants

pubmed: 34713805
doi: 10.7554/eLife.69832
pii: 69832
pmc: PMC8639150
doi:
pii:

Substances chimiques

Cell-Penetrating Peptides 0
Potassium Channels 0

Banques de données

SRA
['SRP161445']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021, Trofimenko et al.

Déclaration de conflit d'intérêts

ET, GG, MH, NC, MD, GD, YA, MS, SM, GV, FO, LD, JP, FA, AL, AD, CW No competing interests declared

Références

Phys Chem Chem Phys. 2018 Feb 14;20(7):5180-5189
pubmed: 29393934
Photochem Photobiol. 2014 Mar-Apr;90(2):448-454
pubmed: 24188468
Drug Chem Toxicol. 1985;8(6):451-68
pubmed: 4092618
Nucleic Acids Res. 1996 Feb 15;24(4):596-601
pubmed: 8604299
Biochemistry. 1998 May 5;37(18):6235-9
pubmed: 9572837
J Chem Theory Comput. 2008 May;4(5):819-34
pubmed: 26621095
J Chem Theory Comput. 2015 Sep 8;11(9):4486-94
pubmed: 26575938
Int J Cancer. 2014 Jul 1;135(1):242-7
pubmed: 24347041
Cancer Res. 1986 Nov;46(11):5518-23
pubmed: 3756900
Hum Mol Genet. 2011 Aug 15;20(16):3151-60
pubmed: 21576124
Mol Pharm. 2009 May-Jun;6(3):836-48
pubmed: 19278221
J Control Release. 2017 Jun 28;256:68-78
pubmed: 28411183
Pharmacol Rev. 2000 Dec;52(4):557-94
pubmed: 11121510
J Am Chem Soc. 2004 Aug 11;126(31):9506-7
pubmed: 15291531
J Control Release. 2018 Apr 10;275:107-116
pubmed: 29452131
Biochim Biophys Acta Biomembr. 2019 Nov 1;1861(11):183035
pubmed: 31394098
Bioconjug Chem. 2008 Dec;19(12):2363-74
pubmed: 19053306
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Curr Pharm Des. 2013;19(16):2863-8
pubmed: 23140459
Cell. 1988 Dec 23;55(6):1189-93
pubmed: 2849510
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Biophys J. 1978 May;22(2):307-40
pubmed: 77689
Annu Rev Phys Chem. 2012;63:595-617
pubmed: 22404588
J Am Chem Soc. 2014 Oct 15;136(41):14554-9
pubmed: 25229711
Biochim Biophys Acta. 2016 Oct;1858(10):2266-2277
pubmed: 26748016
Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):11923-11928
pubmed: 30397112
J Biomech. 2018 May 17;73:137-144
pubmed: 29631749
Cell. 2015 Apr 23;161(3):674-690
pubmed: 25910214
Biomed Pharmacother. 2018 Jul;103:982-988
pubmed: 29710515
J Pept Res. 2000 Nov;56(5):318-25
pubmed: 11095185
J Control Release. 2012 Jul 20;161(2):582-91
pubmed: 22516088
Eur J Biochem. 2002 Jun;269(12):2918-26
pubmed: 12071955
Ther Deliv. 2013 May;4(5):573-91
pubmed: 23647276
Biochim Biophys Acta. 2007 Sep;1768(9):2011-25
pubmed: 17572379
Biochim Biophys Acta. 2012 Nov;1818(11):2669-78
pubmed: 22705501
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12684-8
pubmed: 25136100
Cytometry A. 2009 Jul;75(7):593-608
pubmed: 19504578
J Pept Sci. 2005 Jul;11(7):401-9
pubmed: 15635670
Biochim Biophys Acta. 1998 Nov 11;1414(1-2):127-39
pubmed: 9804921
PLoS Comput Biol. 2016 Jan 08;12(1):e1004699
pubmed: 26745628
Biochemistry. 2005 Aug 2;44(30):10189-98
pubmed: 16042396
Nat Med. 2004 Mar;10(3):310-5
pubmed: 14770178
Biochim Biophys Acta. 2015 Feb;1848(2):593-602
pubmed: 25445669
Trends Mol Med. 2012 Jul;18(7):385-93
pubmed: 22682515
Nanoscale. 2019 Jan 23;11(4):1949-1958
pubmed: 30644958
ACS Nano. 2013 Dec 23;7(12):10799-808
pubmed: 24251827
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20805-10
pubmed: 18093956
iScience. 2021 Jul 30;24(8):102923
pubmed: 34430812
Traffic. 2007 Jul;8(7):848-66
pubmed: 17587406
Calif Med. 1953 May;78(5):417-23
pubmed: 13042672
Nucleic Acids Res. 2016 Jul 8;44(W1):W449-54
pubmed: 27131374
J Bioenerg Biomembr. 2020 Oct;52(5):321-342
pubmed: 32715369
PLoS Comput Biol. 2010 Jun 10;6(6):e1000810
pubmed: 20548957
J Phys Chem B. 2014 Aug 21;118(33):9909-18
pubmed: 24986456
J Biol Chem. 2001 Aug 24;276(34):32040-5
pubmed: 11425865
Arch Biochem Biophys. 1995 Nov 10;323(2):279-87
pubmed: 7487089
Acc Chem Res. 2017 Oct 17;50(10):2449-2456
pubmed: 28910080
J Membr Biol. 2010 Jul;236(1):15-26
pubmed: 20623351
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8151-6
pubmed: 10884437
Q Rev Biophys. 2011 Feb;44(1):123-51
pubmed: 21108866
J Comput Chem. 2008 Aug;29(11):1859-65
pubmed: 18351591
Sci Rep. 2016 Feb 22;6:21759
pubmed: 26899474
PLoS One. 2015 Mar 31;10(3):e0120487
pubmed: 25826368
Sci Rep. 2016 Nov 14;6:36938
pubmed: 27841303
J Phys Chem B. 2008 May 8;112(18):5547-50
pubmed: 18412411
Biophys J. 2009 Oct 7;97(7):1917-25
pubmed: 19804722
PLoS One. 2017 Oct 31;12(10):e0186816
pubmed: 29088239
Mol Ther. 2008 Apr;16(4):698-706
pubmed: 18362927
J Phys Chem B. 2010 May 27;114(20):6855-65
pubmed: 20429602
Hum Mol Genet. 2009 Nov 15;18(22):4405-14
pubmed: 19692354
Front Physiol. 2013 Jul 17;4:185
pubmed: 23882223
Biophys J. 2010 Sep 8;99(5):1447-54
pubmed: 20816056
Biochem J. 2015 Oct 15;471(2):221-30
pubmed: 26272944
Trends Pharmacol Sci. 2017 Apr;38(4):406-424
pubmed: 28209404
J Photochem Photobiol B. 1995 Apr;28(1):93-9
pubmed: 7791010
Nature. 2014 Jul 31;511(7511):596-600
pubmed: 25043046
J Virol. 2019 Mar 5;93(6):
pubmed: 30626681
Nature. 2018 Feb 1;554(7690):118-122
pubmed: 29364876
J Phys Chem B. 2015 Jul 2;119(26):8239-46
pubmed: 26042722
Annu Rev Biophys. 2008;37:175-95
pubmed: 18573078
Biophys J. 2010 Sep 8;99(5):1455-64
pubmed: 20816057
Biopolymers. 2011 Oct;95(10):722-31
pubmed: 21538329
J Phys Chem B. 2013 Oct 10;117(40):11906-20
pubmed: 24007457
J Am Chem Soc. 2007 Aug 22;129(33):10126-32
pubmed: 17658882
J Biol Chem. 1999 Oct 1;274(40):28198-205
pubmed: 10497173
Biochim Biophys Acta Biomembr. 2020 Feb 1;1862(2):183098
pubmed: 31676372
Bioconjug Chem. 2008 Mar;19(3):656-64
pubmed: 18269225
J Chem Theory Comput. 2009 Sep 8;5(9):2531-43
pubmed: 26616630
Biophys J. 2004 Apr;86(4):2156-64
pubmed: 15041656
Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1864-8
pubmed: 1672046
Biophys J. 2007 Mar 15;92(6):1878-90
pubmed: 17208976
Methods Enzymol. 2004;383:94-118
pubmed: 15063648
J Glob Antimicrob Resist. 2021 Jun;25:227-231
pubmed: 33852935
Biochemistry. 2005 Jan 11;44(1):138-48
pubmed: 15628854
J Photochem Photobiol B. 2007 Jul 27;88(1):29-35
pubmed: 17560792
Biomater Res. 2016 Sep 07;20(1):28
pubmed: 27606074
Biophys J. 2008 Aug;95(4):1837-50
pubmed: 18469089
Cell. 1988 Dec 23;55(6):1179-88
pubmed: 2849509
Oncotarget. 2016 Sep 27;7(39):64342-64359
pubmed: 27602963
J Chem Theory Comput. 2015 May 12;11(5):2144-55
pubmed: 26574417
J Biol Chem. 1994 Apr 8;269(14):10444-50
pubmed: 8144628
FEBS Lett. 2013 Jun 19;587(12):1693-702
pubmed: 23669356
Nat Neurosci. 2008 Jun;11(6):683-92
pubmed: 18488023
Front Microbiol. 2017 Jun 07;8:994
pubmed: 28638371
Biochemistry. 2011 May 31;50(21):4650-64
pubmed: 21491915
J Biol Chem. 2000 Aug 4;275(31):24089-95
pubmed: 10816588
Phys Rev Lett. 2008 Jan 18;100(2):020603
pubmed: 18232845
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31871-31881
pubmed: 33257567
Chem Rev. 2019 May 8;119(9):6184-6226
pubmed: 30623647
Bioconjug Chem. 2018 Apr 18;29(4):1102-1110
pubmed: 29489340
Biochemistry. 2010 Feb 23;49(7):1549-55
pubmed: 20095636
BMC Biochem. 2004 Jul 19;5:10
pubmed: 15260890
Nucleic Acids Res. 2007;35(13):4495-502
pubmed: 17584792
PLoS One. 2014 Oct 02;9(10):e109243
pubmed: 25275375
J Phys Chem B. 2015 Jan 22;119(3):736-42
pubmed: 25046020
J Control Release. 2010 Oct 15;147(2):171-9
pubmed: 20620184
Biochemistry. 2004 Mar 9;43(9):2438-44
pubmed: 14992581
Radiat Res. 2017 May;187(5):562-569
pubmed: 28323576
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5567-72
pubmed: 16567637
Biochim Biophys Acta. 2012 Feb;1818(2):294-302
pubmed: 22001851
J Chem Phys. 2009 May 21;130(19):195105
pubmed: 19466869
J Cell Sci. 2017 Sep 15;130(18):3124-3140
pubmed: 28754686
J Neurochem. 2007 Aug;102(3):789-800
pubmed: 17437546
Biochemistry. 2005 Feb 22;44(7):2692-702
pubmed: 15709783
Pharmaceuticals (Basel). 2010 Mar 30;3(4):961-993
pubmed: 27713284
J Phys Chem B. 2008 Oct 30;112(43):13588-96
pubmed: 18837540
Biophys J. 2004 Jan;86(1 Pt 1):254-63
pubmed: 14695267
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6817-22
pubmed: 23572592
FASEB J. 2013 Feb;27(2):738-49
pubmed: 23070606
Cell Rep. 2021 Nov 2;37(5):109945
pubmed: 34731620
Oncogene. 2004 Nov 25;23(55):8971-8
pubmed: 15467750
J Chem Phys. 2007 Jan 7;126(1):014101
pubmed: 17212484
Beilstein J Nanotechnol. 2020 Jan 9;11:101-123
pubmed: 31976201
J Natl Cancer Inst. 2009 Jun 3;101(11):828-32
pubmed: 19470951
Mol Ther. 2012 May;20(5):984-93
pubmed: 22334015
Biochim Biophys Acta. 1998 Oct 15;1375(1-2):52-60
pubmed: 9767105
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Biophys. 2011;2011:414729
pubmed: 21687343
Biochemistry. 2003 Aug 5;42(30):8999-9006
pubmed: 12885232
Chem Phys Lipids. 2013 Apr;169:95-105
pubmed: 23415670
J Phys Chem B. 2007 Jul 12;111(27):7812-24
pubmed: 17569554
Chem Soc Rev. 2013 Aug 21;42(16):6801-22
pubmed: 23708257
Cold Spring Harb Protoc. 2012 Apr 01;2012(4):459-64
pubmed: 22474652
Biophys J. 2020 Jan 7;118(1):57-69
pubmed: 31810658
Biophys J. 2008 May 1;94(9):3393-404
pubmed: 18212019
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):580-97
pubmed: 18045730
Plant J. 2003 Oct;36(2):280-90
pubmed: 14535891

Auteurs

Evgeniya Trofimenko (E)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Gianvito Grasso (G)

Dalle Molle Institute for Artificial Intelligence Research, Università della Svizzera italiana, Scuola Universitaria Professionale della Svizzera Italiana, Lugano, Switzerland.

Mathieu Heulot (M)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Nadja Chevalier (N)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Marco A Deriu (MA)

PolitoBIOMed Lab Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino, Italy.

Gilles Dubuis (G)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Yoan Arribat (Y)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Marc Serulla (M)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Sebastien Michel (S)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Gil Vantomme (G)

Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.

Florine Ory (F)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Linh Chi Dam (LC)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Julien Puyal (J)

Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.
CURML (University Center of Legal Medicine), Lausanne University Hospital, Lausanne, Switzerland.

Francesca Amati (F)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Anita Lüthi (A)

Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.

Andrea Danani (A)

Dalle Molle Institute for Artificial Intelligence Research, Università della Svizzera italiana, Scuola Universitaria Professionale della Svizzera Italiana, Lugano, Switzerland.

Christian Widmann (C)

Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH